

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**OrbusNeich Medical Group Holdings Limited**

**業聚醫療集團控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6929)**

**VOLUNTARY ANNOUNCEMENT  
INVESTMENT IN AND CONSTRUCTION OF  
THE RESEARCH AND DEVELOPMENT AND  
PRODUCTION BASE FOR VASCULAR INTERVENTIONAL  
MEDICAL DEVICES IN FUCHUN BAY NEW TOWN, HANGZHOU**

This is a voluntary announcement made by OrbusNeich Medical Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”).

The board of directors (the “**Board**”) of the Company is pleased to hereby inform the shareholders and potential investors of the Company of the attached press release, where the Company’s wholly-owned subsidiary, OrbusNeich Medical (Zhejiang) Company Limited, has entered into a commercial agreement with Hangzhou Fuchun Bay New Town Management Committee in relation to the investment in and construction of a research and development (R&D) and production base for vascular interventional medical devices (the “**Project**”), in order to meet the Company’s medium to long-term market demand and for effective capacity allocation. This Project may involve transactions with various entities in land acquisition and the construction of facilities. The Company will comply with the applicable requirements under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as appropriate.

Implementation of the Project is subject to factors such as relevant policies, macro-economy, industry cycle and market changes which make it susceptible to uncertainties; therefore, shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**OrbusNeich Medical Group Holdings Limited**  
**Mr. David CHIEN**  
*Chairman, Executive Director and Chief Executive Officer*

Hong Kong, March 28, 2023

*As at the date of this announcement, the Board comprises Mr. David CHIEN, Ms. Kwai Ching Denise LAU, Mr. Wing Shing CHEN and Mr. Ching Chung John CHOW as Executive Directors; Dr. Yi ZHOU as Non-Executive Director; and Mr. Yip Keung CHAN, Mr. Ka Keung LAU BBS, MH, JP and Dr. Lai Fan Gloria TAM as Independent Non-executive Directors.*

## **OrbusNeich Plans to Set up Its Largest R&D and Production Base in Fuchun Bay New Town, Hangzhou**

### **Introduction**

Hong Kong, 28 March 2023 — OrbusNeich Medical (Zhejiang) Company Limited (“**OrbusNeich Zhejiang**”), a wholly-owned subsidiary of OrbusNeich Medical Group Holdings Limited (“**OrbusNeich**” or the “**Group**”; stock code: 6929), a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures, today entered into a commercial agreement with Hangzhou Fuchun Bay New Town Management Committee in relation to the investment in and construction of an R&D and production base for vascular interventional medical devices (the “**Project**”), with investment in fixed assets amounting to approximately RMB300 million. Upon completion of construction and commencement of production, the Project is expected to have an annual production capacity of approximately 2.4 million units of products.

### **Scope and investment amount of the Project**

Pursuant to the commercial agreement, the Group is to build its R&D and production base in Fuchun Bay New Town, Hangzhou, on a site of about 20,000 m<sup>2</sup> and with construction area reaching 50,000 m<sup>2</sup>. When completed, the facility will focus mainly on R&D and production of medical devices such as PCI and PTA intervention products, as well as structural heart disease interventional products, among others. The land parcel destined for industrial use will be sold by the Ministry of Natural Resources through open tender, auction and listing in open market. OrbusNeich Zhejiang will follow the required procedures to obtain land use right.

### **Reasons for and benefits of the Agreement**

**Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich**, said, “Since listed on HKEX last December, the Group has pushed forward with implementing its corporate development strategies, with capacity expansion being an important component. In recent years, Fuchun Bay New Town has vigorously developed such emerging strategic industries as information technology, artificial intelligence, biotechnology, high-end equipment, with preferential policies in place in relation to land, talent and R&D for such enterprises. As a major global medical device manufacturer owning more than 180 granted patents, OrbusNeich setting up an operation base there will bring new and advanced technologies into the region and facilitate local industrial upgrading. We believe the cooperation will benefit the development of both the Group and Fuchun Bay New Town.”

Currently, the Group has production facilities in Shenzhen, the PRC and Hoevelaken, the Netherlands, with an aggregate annual designed capacity of approximately 1,350,000 units of balloon products and approximately 56,000 units of stent products. According to the report from China Insights Industry Consultancy (“**CIC Report**”), the global PCI instruments and PTA instruments markets are expected to grow at a CAGR of 12.1% and 11.1%, respectively, between 2021 and 2030, pointing to huge growth potential. For the Group, it has in the pipeline about 40 products in different development stages for new business segments such as neuro-intervention and structural heart disease intervention products, and new product series. All circumstances considered, the Group expects its existing production capacity to be saturated in the future, commanding building of new production facilities to meet medium to long-term market demand and for effective capacity allocation.

Fuchun Bay New Town is in Fuyang District, Hangzhou. After the completion of construction of the new base, it will not only be the Group’s largest R&D and production facility, but also a strategic location in the Yangtze River Delta. Capitalizing on the advantages of Yangtze River Delta as a transportation hub and talent pool, the Group can expand its production capacity, while enhancing its overall operational capabilities.

#### **About OrbusNeich Medical Group Holdings Limited**

OrbusNeich is a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells products to over 70 countries and regions worldwide, and it is also the only PCI balloon manufacturer headquartered in China that ranked among the top 6 players in all major overseas PCI balloon markets including Japan (Ranked No. 2), Europe (Ranked No. 4), and the U.S. (Ranked No. 6) in terms of sales volume of PCI balloons in 2021 in accordance with the CIC Report. In addition, in terms of sales volume of PTA balloons in 2021, it ranked No. 3 in Japan and No. 4 in the U.S., respectively. It also specializes in coronary stent products and is actively expanding into neuro vascular intervention and structural heart disease areas. OrbusNeich owns more than 180 granted patents globally as of December 2022. Its in-house R&D team has over twenty years of product development experience and has developed proprietary, world leading technologies.

For more details, please visit the Group’s official website: <https://orbusneich.com/>

#### **About Hangzhou Fuchun Bay New Town Management Committee**

Hangzhou Fuchun Bay New Town Management Committee was established in January 2013. It is authorized by the Fuyang District Government of Hangzhou to develop, build and manage the Fuchun Bay New Town. It is responsible for construction in mainly the key area that reaches south of Fuchun River and parts north of the Hangzhou-Qiandaohu Expressway, spanning in all about 53.3 km<sup>2</sup>, with the goal of building in the area a new green industry-city integrated town that has creative and

intelligent R&D, energetic entrepreneurship, smart manufacturing, cultural and leisure offerings, tourism and sight-seeing experiences, and transportation convenience all under one roof.

To the best knowledge and belief of the directors of the Company (the “**Directors**”), Hangzhou Fuchun Bay New Town Management Committee is a third party independent of the Company and connected persons of the Company (as defined by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The agreement sets out a framework for the Group’s investment in and construction of an R&D and production base in Fuchun Bay New Town, the PRC and the support and assistance to be provided by the local government. The Project may involve transactions with various entities in land acquisition and the construction of facilities. The Company will comply with the applicable requirements under the Listing Rules as appropriate.

### **Forward-Looking Statements**

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.